This might support the conclusion that the presence of PD-L1+CTC is not significantly correlated with the treatment outcomes of nivolumab, a PD-1 inhibitor, and a higher baseline PD-L1+CTC number does not lead to a response in patients with advanced NSCLC [172]. Here, CD274 is linked to non-small cell lung carcinoma.